Glutamate-based Therapies for Psychiatric Disorders
Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the t...
Uloženo v:
| Korporativní autor: | |
|---|---|
| Další autoři: | |
| Médium: | Elektronický zdroj E-kniha |
| Jazyk: | English |
| Vydáno: |
Basel :
Birkhäuser Basel : Imprint: Birkhäuser,
2010.
|
| Vydání: | 1st ed. 2010. |
| Edice: | Milestones in Drug Therapy,
|
| Témata: | |
| On-line přístup: | https://doi.org/10.1007/978-3-0346-0241-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|
Obsah:
- N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression
- Ionic Glutamate Modulators in Depression (Zinc, Magnesium)
- Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy
- Glutamatergic Modulators for the Treatment of Major Depressive Disorder: Metabotropic Glutamate Receptors
- Positive Modulation of AMPA Receptors as a Broad-Spectrum Strategy for Treating Neuropsychiatric Disorders
- Activation of Group II Metabotropic Glutamate Receptors (mGluR2 and mGluR3) as a Novel Approach for Treatment of Schizophrenia
- mGluR1 Negative Allosteric Modulators: An Alternative Metabotropic Approach for the Treatment of Schizophrenia
- Metabotropic Glutamate Receptors as Targets for the Treatment of Drug and Alcohol Dependence
- Metabotropic Approaches to Anxiety.